Harvard Title
Assistant Professor of Neurology
Other Affiliations
Brigham and Women's Hospital
Harvard Vanguard Medical Associates
Address
Harvard Vanguard Medical Associates
111 Grossman Dr
Braintree MA 02184
Publications View
Ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer refractory to docetaxel-based therapy: A phase II study of the DOD Prostate Cancer Clinical Trials Consortium.
Authors: Small E, Harzstark A, Weinberg VK, Smith DC, Mathew P, Beer T, Liu G, Sharib J, Rosenberg J.
J Clin Oncol
View full abstract on Pubmed
J Clin Oncol
View full abstract on Pubmed
Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer.
Authors: Mathew P, Pisters LL, Wood CG, Papadopoulos JN, Williams DL, Thall PF, Wen S, Horne E, Oborn CJ, Langley R, Fidler IJ, Pettaway CA.
J Urol
View full abstract on Pubmed
J Urol
View full abstract on Pubmed
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.
Authors: Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SF, Ryan C, Logothetis C, Scher HI.
Clin Genitourin Cancer
View full abstract on Pubmed
Clin Genitourin Cancer
View full abstract on Pubmed
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
Authors: Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, Mathew P, Pagliaro L, Wood C, Jonasch E.
J Urol
View full abstract on Pubmed
J Urol
View full abstract on Pubmed
Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer.
Authors: Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ.
Clin Cancer Res
View full abstract on Pubmed
Clin Cancer Res
View full abstract on Pubmed
Phase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC).
Authors: Taplin M, Ko Y, Regan MM, Beer TM, Carducci MA, Mathew P, Bubley G, Oh WK, Kantoff PW, Balk SP.
J Clin Oncol
View full abstract on Pubmed
J Clin Oncol
View full abstract on Pubmed
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases.
Authors: Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ.
Clin Cancer Res
View full abstract on Pubmed
Clin Cancer Res
View full abstract on Pubmed
Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference.
Authors: Kantoff PW, Beer TM, D'Amico AV, Dipaola RS, Eisenberger MA, Hussain MH, Kelly WK, Mathew P, Morris MJ, Ryan CJ, Sandler HM, Thompson IM, Carroll PR.
J Urol
View full abstract on Pubmed
J Urol
View full abstract on Pubmed
Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer.
Authors: Mathew P, Logothetis CJ, Dieringer PY, Chen I, Pagliaro LC, Bekele BN, Zhou X, Daliani DD.
Clin Genitourin Cancer
View full abstract on Pubmed
Clin Genitourin Cancer
View full abstract on Pubmed
Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma.
Authors: Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM.
Cancer
View full abstract on Pubmed
Cancer
View full abstract on Pubmed